Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Acorda Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-158.0 Mil. Acorda Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $108.5 Mil.
Therefore, Acorda Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -1.46.
The historical rank and industry rank for Acorda Therapeutics's Equity-to-Asset or its related term are showing as below:
ACORQ'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.46 Med: 0.41 Max: 0.54
Current: -1.46
During the past 13 years, the highest Equity to Asset Ratio of Acorda Therapeutics was 0.54. The lowest was -1.46. And the median was 0.41.
ACORQ's Equity-to-Asset is ranked worse than 94.94% of 1087
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs ACORQ: -1.46
Acorda Therapeutics Equity-to-Asset Historical Data
The historical data trend for Acorda Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acorda Therapeutics's Equity-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's Equity-to-Asset falls into.
Acorda Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Acorda Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Acorda Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your 